Clinical Trial Eligibility in Real-World Alopecia Areata Patients Treated With Baricitinib

    January 2026 in “ Dermatologic Therapy ”
    Daniel Muñoz‐Barba, Miguel Limeres de la Rosa, Andrea Isabel Rodriguez-Sanna … Salvador Arias‐Santiago
    Studysummary This study found that only a small percentage of alopecia areata patients treated with baricitinib in real-world settings would have met the eligibility criteria used in clinical trials.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 21

    1. Effectiveness And Safety Of Baricitinib In Alopecia Areata: A Prospective Cohort Study Journal of Dermatological Treatment · 2025
    2. Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib Journal of Clinical Medicine · 2025
    3. Effectiveness and Safety of Baricitinib in Severe Alopecia Areata: 48-Week Results Journal of the European Academy of Dermatology and Venereology · 2025
    4. Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study Dermatology and Therapy · 2025
    5. Real-Life Effectiveness and Safety of Baricitinib in Adults with Alopecia Areata: A Multicenter Study Journal of the European Academy of Dermatology and Venereology · 2025
    6. Effectiveness of Baricitinib in Alopecia Areata Patients With a Current Episode Lasting Longer Than 8 Years: An Italian Multicenter Real-Life Experience in the Lazio Region International Journal of Dermatology · 2025
    7. Switching JAK Inhibitors: Evaluating Baricitinib’s Effectiveness in Alopecia Areata After Tofacitinib Failure Archives of Dermatological Research · 2025
    8. Predictive Factors for Treatment Responses to Baricitinib in Severe Alopecia Areata: A Retrospective, Multivariate Analysis of 70 Cases from a Single Center The Journal of Dermatology · 2025
    9. Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study Journal of the European Academy of Dermatology and Venereology · 2025
    10. Biologics And Small Molecule Targeted Therapies For Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, And Hidradenitis Suppurativa In The US: A Narrative Review Children · 2024
    11. Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2 Journal of the European Academy of Dermatology and Venereology · 2024
    12. Treatment of Moderate-to-Severe Alopecia Areata in Patients Over the Age of 65 With Baricitinib Clinical and Experimental Dermatology · 2024
    13. Effectiveness and Safety of Baricitinib in Patients With Moderate-to-Severe Refractory Alopecia Areata in Real World: An Open-Label, Single-Center Study Journal of Cosmetic Dermatology · 2023
    14. Effectiveness and Safety of Baricitinib in Patients With Severe Alopecia Areata: A 36-Week Multicenter Real-World Experience Journal of Dermatological Treatment · 2023
    15. Major Improvement of Very Severe Alopecia Areata in Patients Treated With the Combination of Baricitinib and Low Doses of Corticosteroids: An Eight-Case Series Clinical and Experimental Dermatology · 2023
    16. Alopecia Areata: An Updated Review for 2023 Journal of Cutaneous Medicine and Surgery · 2023
    17. Switching Between Tofacitinib and Baricitinib in Alopecia Areata: A Review of Clinical Response Journal of the American Academy of Dermatology · 2023
    18. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
    19. Alopecia Areata: A Review on Diagnosis, Immunological Etiopathogenesis, and Treatment Options Clinical and Experimental Medicine · 2021
    20. Development of Clinician-Reported Outcome and Patient-Reported Outcome Measures for Eyebrow, Eyelash, and Nail Assessment in Alopecia Areata American Journal of Clinical Dermatology · 2020
    21. SALT II: A New Take on the Severity of Alopecia Tool for Determining Percentage Scalp Hair Loss Journal of The American Academy of Dermatology · 2016